Pharming Group N.V. (PHAR) Receivables - Net (2019 - 2024)

Pharming (PHAR) has disclosed Receivables - Net for 6 consecutive years, with $41.5 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables - Net fell 10.02% year-over-year to $41.5 million, compared with a TTM value of $41.5 million through Dec 2024, down 10.02%, and an annual FY2024 reading of $41.5 million, down 10.02% over the prior year.
  • Receivables - Net was $41.5 million for Q4 2024 at Pharming, down from $46.2 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $46.2 million in Q4 2023 and bottomed at $21.0 million in Q4 2022.
  • Average Receivables - Net over 5 years is $34.7 million, with a median of $34.8 million recorded in 2020.
  • The sharpest move saw Receivables - Net crashed 30.08% in 2022, then surged 120.18% in 2023.
  • Year by year, Receivables - Net stood at $34.8 million in 2020, then dropped by 13.88% to $30.0 million in 2021, then plummeted by 30.08% to $21.0 million in 2022, then skyrocketed by 120.18% to $46.2 million in 2023, then decreased by 10.02% to $41.5 million in 2024.
  • Business Quant data shows Receivables - Net for PHAR at $41.5 million in Q4 2024, $46.2 million in Q4 2023, and $21.0 million in Q4 2022.